Sight Sciences Inc. Common Stock (SGHT)

FairStock Score: 50/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with the business: Sight Sciences sells ophthalmic devices, including the OMNI system for surgical glaucoma and products for dry eye. It has a real clinical niche with 186 employees, but scale is small. In fiscal 2025, the year ended 2025-12-31, revenue was $77.4M and net income was -$38.4M. In fiscal 2024, revenue was $79.9M and net income was -$51.5M, and in fiscal 2023, revenue was $81.1M and net income was -$55.5M. So losses are shrinking, but the top line actually contracted from 2023 to 2025. The latest fiscal Q2 2026, the quarter ended 2026-06-30, showed revenue of $23.4M and net income of -$4.4M, with diluted EPS of -$0.08, versus fiscal Q2 2025, the quarter ended 2025-06-30, revenue of $19.6M and net income of -$11.9M. That is progress, but one quarter does not make a moat. Competitive advantages in medical devices come from surgeon loyalty, reimbursement, and clinical data; the figures alone do not prove durable pricing power. Financial health is weak: trailing free cash flow is -$23.3M, and FairStock calculations from the given data show FCF yield of -5.0%, Piotroski 3/9, Altman Z 0.99, debt/equity 0.79, ROE -48.42%, and ROCE -10.84%. At the $8.39 close on 2026-10-13, FairStock shows P/B 8.65 and P/E -15.25; the market cap is $462.2M. Paying 8.65 times book for a loss-making, cash-burning company is not Graham's idea of cheap. The Lynch category is none because filings show losses in each of the last four years. Growth could eventually justify the value, but only if losses turn into cash profits and revenue reaccelerates.

In plain English: Sight Sciences makes medical devices for eye conditions such as glaucoma and dry eye. The business is still unprofitable and uses more cash than it brings in, although the latest filed quarter showed higher sales and a smaller loss than a year earlier. At $8.39 a share, the price looks rich compared with its accounting value and current lack of profits, so much depends on future growth and reaching break-even.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer